PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | |type 2 diabetes |
| Sentences | 223 |
| PubMedID- 21525446 | Figure 1 summarizes how micro- and macrovascular disease in type 2 diabetes could share common pathways (14). |
| PubMedID- 23173143 | The tosca.it trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. |
| PubMedID- 26130877 | Winners in each category were as follows: best fellow poster, "diet pattern and cardiovascular disease among women with type 2 diabetes mellitus," by hyun joon shin, md; best resident poster, "oral squamous cell carcinoma: current concepts in imaging, staging, and fibular osteocutaneous free-flap reconstruction," by r. |
| PubMedID- 26055067 | This paper describes the relationship of baseline fgf21 levels and new on-study microvascular disease in patients with type 2 diabetes from the field study. |
| PubMedID- 23385371 | While some authorities, primarily those funded by the food industry, have argued that the high amounts of added sugars in food and beverages may contribute to health risks solely as a consequence of their caloric content, there is also mounting evidence that fructose may have a specific ability to cause fatty liver (which can progress to cirrhosis of the liver), high triglycerides in blood (which can contribute to cardiovascular disease), insulin resistance (leading to type 2 diabetes) and increased appetite (which obviously can lead to obesity) [5,6]. |
| PubMedID- 22833161 | The aim of this study was to investigate the relationship between daily salt intake and albuminuria, a marker of diabetic nephropathy and cardiovascular disease, in patients with type 2 diabetes. |
| PubMedID- 22973260 | This effect may have a major impact on the attenuation of atherosclerosis and may help in the design of new therapies for cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 24602748 | [primary prevention of cardiovascular disease with statin in type 2 diabetes mellitus: is it time to change our strategy. |
| PubMedID- 22891258 | This study is the largest prospective analysis specifically addressing hdl-c level and risk of microvascular disease in patients with type 2 diabetes. |
| PubMedID- 26252223 | Dyslipidemia is a strong risk factor for cardiovascular disease among patients with type 2 diabetes (t2d). |
| PubMedID- 23113179 | Therefore, higher rates of cardiovascular disease because of type 2 diabetes, among people with lower socioeconomic characteristics are expected and demonstrated in several studies (8, 20). |
| PubMedID- 20228404 | Background: we investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease. |
| PubMedID- 23951913 | Therefore, increase in glycosylated hemoglobin should be considered a predictor of cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 25899452 | Statins have been shown to be beneficial in reducing cardiovascular disease (cvd) in patients with type 2 diabetes [1, 2], but it remains unclear whether these effects can be explained by their lipid-lowering effects only. |
| PubMedID- 23439986 | Profile of microvascular disease in type 2 diabetes in a tertiary health care hospital in india. |
| PubMedID- 22247905 | Cimt, fmd, and pwv along with the ukpds risk engine should be considered to evaluate cardiovascular disease risk in patients with newly diagnosed type 2 diabetes. |
| PubMedID- 21625418 | The goal for non-hdl cholesterol has been reported to be the level of ldl cholesterol plus 30 mg/dl.36 in type 2 diabetics, several characteristics such as elevated triglycerides, decreased hdl cholesterol, and elevated small dense ldl, are well-known.25 because non-hdl cholesterol reflects all apolipoprotein b-containing atherogenic lipoproteins, non-hdl cholesterol may be useful in predicting cardiovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 22040602 | Recessive protective effect of adipoq rs1501299 on cardiovascular diseases with type 2 diabetes: a meta-analysis. |
| PubMedID- 23035799 | Hypertension and dyslipidemia constitute major public health problems as they increase the risk of cardiovascular diseases (cvds), especially in patients with concomitant type 2 diabetes (t2d)[1-4]. |
| PubMedID- 24107845 | Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 21756323 | Although mmp-9 seems to reflect an overall burden of vascular disease in type 2 diabetes patients [8-13] it is still controversially discussed to use it as a reliable surrogate marker of cv risk to date [14-16]. |
| PubMedID- 26408873 | High blood glucose level, lipid profile disturbances and plasma homocysteine (hcy) are important risk factors for cardiovascular diseases in patients with type 2 diabetes. |
| PubMedID- 22250063 | Pharmacological treatment is critical in delaying the underlying progression of diabetes (2), yet it remains inadequate in preventing the increased risk of cardiovascular disease (cvd) in patients with type 2 diabetes, especially women (3). |
| PubMedID- 26395643 | Coenzyme q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus. |
| PubMedID- 20034371 | Given the possible correlation between local crp production and the degree of severity of coronary artery disease or the nature of the lesion, such alteration may contribute to the accelerated development of vascular disease in patients with type 2 diabetes. |
| PubMedID- 21736687 | Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing. |
| PubMedID- 26076974 | Many investigations suggest that ceramides are also involved strongly in the pathogenesis of insulin resistance, which together with other metabolic syndrome elements are known to be risk factors of diabetes complications and macrovascular disease in patients with and without type 2 diabetes. |
| PubMedID- 26246173 | Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association. |
| PubMedID- 20532015 | A conference was convened by the korean diabetes association and the korean endocrine society on september 7, 2009 to discuss and organize the results of research on intensive glucose control for the prevention of cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 26029318 | Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. |
| PubMedID- 25150157 | Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. |
| PubMedID- 22822420 | Albuminuria is well known to be a risk factor for renal dysfunction and cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 26566494 | Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies. |
| PubMedID- 25708055 | This study aimed to assess the effects of active and passive smoking exposure on the development of cardiovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 24894815 | Aims: to analyse the effects of hyperglycaemia and hypertension and treatment of diabetes and hypertension on cardiovascular disease incidence in patients with type 2 diabetes with up to 30 years of follow-up. |
| PubMedID- 21390057 | Pulse pressure and systolic night-day ratio interact in prediction of macrovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 20047771 | Leisure-time physical activity and risk of type 2 diabetes in patients with established vascular disease or poorly controlled vascular risk factors. |
| PubMedID- 26516107 | The aim of this study was to analyse all-cause mortality and cardiovascular disease (cvd) outcomes in patients with type 2 diabetes detected by screening or diagnosed clinically. |
| PubMedID- 20526577 | Proteinuria modifies the effects of physical activity on total and cardiovascular disease mortality rates in patients with type 2 diabetes. |
| PubMedID- 19875998 | The impact of obesity on cardiovascular disease (cvd) outcomes in patients with type 2 diabetes mellitus (t2dm) and established coronary artery disease (cad) is controversial; whether bmi and/or waist circumference correlate with atherothrombotic risk factors in such patients is uncertain. |
| PubMedID- 22125626 | The relationship between vascular diseases and hua in patients with type 2 diabetes has not been fully explored. |
| PubMedID- 25467842 | The aim of this meta-analysis was to evaluate the effects of comprehensive lifestyle change, such as diet, exercise, and education, on clinical markers that are risk-factors for cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 23227510 | [a current model for predicting the risk of cardiovascular diseases in patients with type 2 diabetes mellitus]. |
| PubMedID- 22525426 | The prevalence of atherosclerotic cardiovascular disease is higher in patients with type 2 diabetes, a disorder characterized by hyperinsulinemia and insulin resistance. |
| PubMedID- 21129801 | Aims: we aimed to evaluate the association between diabetic microangiopathy and subclinical atherosclerosis as a marker of cardiovascular disease (cvd) risk in patients with newly diagnosed type 2 diabetes. |
| PubMedID- 20040043 | [37] to suggest that rosiglitazone may contribute to a decrease in the development of vascular diseases associated with type 2 diabetes mellitus through actions on pecam-1. |
| PubMedID- 24627833 | The associations between diabetes, subclinical hypothyroidism (sch), and vascular complications have important clinical implications because hypothyroidism itself is a risk factor of atherosclerosis through endothelial dysfunction, and microalbuminuria is an independent marker of cardiovascular diseases in patients with type 2 diabetes. |
| PubMedID- 25526505 | Although the role of glycemic control on microvascular disease in patients with type 2 diabetes was documented in the united kingdom prospective diabetes study24 and other recent studies,4,7 the role of glycemic control for reducing mortality has not yet been established for patients with type 2 diabetes.5–7 although most clinicians agree that effective glycemic control is a desirable intervention for patients with diabetes, the association with increased incidences of hypoglycemia demonstrated in accord, advance and vadt trails has limited the treatment. |
| PubMedID- 21963020 | Preliminary evidence in support of fruit intake for the prevention of cardiovascular disease in patients with type 2 diabetes mellitus (t2dm) is still limited. |
| PubMedID- 20467191 | Effect of exercise intervention on endothelial function and incidence of cardiovascular disease in patients with type 2 diabetes. |